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Few elective surgical procedures are associated with higher
operative risks than pancreatoduodenectomy. In the past,
the operation was burdened by perioperative mortality rates
exceeding 20% and a considerably higher morbidity rate
[1–3]. In a patient series collected between 1977 and 1986
in the West Midlands, UK, Bramhall and colleagues [4]
found a 30-day mortality rate of 28%, and a recent survey
by the Commission on Cancer in USA demonstrated that
mortality rates higher than 10% remain common [5].
However, in later years several experienced centres have
reported markedly improved results of less than 5% [6–9].
In a nationwide study from the Netherlands, 46% of the
pancreatoduodenectomies were performed in hospitals
doing fewer than five operations per year and with a
hospital mortality rate of 16%. In centres doing more
than 25 resections per year, the corresponding figure
was 1.5% [10].
Although if we and other authors [7, 11] previously
pointed to a possible relationship between the
hospital’s/surgeon’s experience of pancreatoduodenectomy
and the outcome of operation, it was not until the 1990s
that this matter was more closely explored. In 1995,
Gordon and associates [12] published a retrospective study
on 501 patients who underwent pancreatoduodenectomy at
one of 39 hospitals in Maryland from 1988 through the first
half of 1993. Hospital mortality rate (2.2% vs 13.5%),
length of stay and costs were significantly less at the high-
volume regional medical centre compared with all other
hospitals. Lieberman and co-workers [13] studied 2233 pan-
creatoduodenectomies or total pancreatectomies performed
in New York State from 1984 to 1991. Hospital mortality
rate was 19% in hospitals where fewer than ten resections
were done during the period, 12% where 10–50 resections
were done, 13% where 51–80 operations were performed
and 6% in hospitals doing more than 81 operations. These
authors also found a higher operative mortality rate for low-
volume surgeons (<9 resections; 16%) compared with high-
volume surgeons (>41 resections; 5%). Glasgow and
Mulvihill [14] carried out a similar study to that of
Lieberman [13] when they used statewide hospital dis-
charge records in California from 1990 to 1994. Among the
298 hospitals, 88% treated an average of two or fewer
patients per year with pancreatic resection. Centres with
higher volume had better profiles in mortality, cost and
length of hospitalisation.
Begg and associates [15] used the Surveillance,
Epidemiology and End Results (SEER) Medicare linked
database to see whether hospital volume was inversely asso-
ciated with 30-day mortality in 5013 patients aged 65 years
or older undergoing different resectional procedures for var-
ious malignancies. Higher volume was linked with lower
mortality rates for pancreatectomy, oesophagectomy, liver
resection and pelvic exenteration, but not for pneumonec-
tomy. There was no evidence that tumour stage varied
according to hospital volume. Birkmeyer and colleagues
[16] performed a national cohort study of 7229 Medicare
patients over 65 years of age undergoing pancreatoduo-
denectomy between 1992 and 1995. Hospitals performing
five to ten operations per year had higher in-hospital mor-
tality rates than the seven hospitals doing ten to 20 opera-
tions or the three hospitals doing 20 or more procedures
annually (6.2% vs 2.5% vs 1.7%, p<0.01).
Simunovic and co-workers [17] reported a population-
based retrospective analysis of 842 pancreatic resections for
cancer performed in Ontario from 1988/89 to 1994/95.
This study differed from the above-mentioned US studies
by representing a publicly financed health care system.
Again, case fatality was associated with hospital volume,
being 14.4%, 12.8% and 3.4%, respectively, for low-,
medium- and high-volume hospitals. Length of stay was
consistently lower in the high-volume group.
The first European study evaluating the higher
volume–better outcome concept was recently published by
Gouma and his colleagues [18] from the Netherlands,
where the medical registry included 1126 partial pancreto-
duodenectomy patients between January 1994 and
December 1998. The annual hospital death rates ranged
from 13.6% to 20% in small-volume hospitals (<5
operations per year) and from 0% to 2.9% in high-volume
hospitals (>25 operations per year).
Although these reports are all retrospective, rely on reg-
istries with dated data, rarely have predefined hypotheses
and may have publication and self-interest biases, most of
them support a volume–outcome relationship in the initial
treatment with curative intent of patients with pancreatic
cancer. The problem of case mix was analysed in three stud-
ies [14,15,19]. No difference in comorbidity, stage of disease
or age was found for high- and low-volume hospitals. It is
important to recognise that within the low- and medium-
volume groups, individual hospitals had widely differing
mortality rates. Although some surgeons had low mortality
rates even in low-volume hospitals, the influence of the
surgeon’s volume on outcomes (where studied) was less
important than the hospital volume [13,19], emphasising
the role of the multidisciplinary speciality treatment team.
In the single study by Wade and co-workers [20], a
positive volume–outcome relation was not obtained. It is
likely that this negative finding resulted from a lack of
high-volume centres in the analysis.
Birkmeyer and associates [21] investigated the possible
influence of hospital volume on late survival after pancre-
atoduodenectomy for cancer in patients over the age of 65.
They found a higher three-year survival at high-volume
hospitals (37%) than at those with medium (29%), low
(26%) or very low volume (25%) (p<0.0001). In a
National Health Service (NHS) report from the UK on
patients treated at 23 hospitals [22], it was found that the
risk of death among patients with pancreatic cancer treated
in hospitals that dealt with one new case each week was
36% lower than for those treated in hospitals that dealt
with one new case a month. These data indicate that
hospital volume influences both perioperative risk and
long-term survival after pancreatoduodenectomy for can-
cer. It may be of interest to mention that the NHS in a
recent report [23] recommend that Pancreatic Cancer
Teams should aim to draw patients from populations of
2–4 million.
As resection is the only way to cure a patient with
pancreatic cancer, it is of the utmost importance that all
patients with resectable disease are offered a safe and proper
operation. This objective implies that surgeons get ade-
quate training and that there are units with a sufficient
patient load to build up broad competence to serve as train-
ing centres. We recently carried out an inquiry including 48
Swedish hospitals (unpublished). Half of them were per-
forming pancreatoduodenectomies, and the majority did
fewer than three such operations a year.
Against the above backdrop [12–19], the concentration
of pancreatic resections to fewer hospitals is recommended
to improve the overall outcome of the operation. However,
such concentration is equally important to guarantee
appropriate training of future pancreatic surgeons. A third
reason is to pave the way for clinical research by building
up sufficiently large patient volumes.
Data are, thus, accumulating that reasonable hospital
volume is a plausible predictor of outcome after pancreato-
duodenectomy for cancer. Even if the skill of the individual
surgeon is important, it seems to be even more crucial that
the multidisciplinary treatment team of surgeons, radiolo-
gists, endoscopists, anaesthetists, pathologists, radiothera-
pists, oncologists and specialised nurses develop substantial
experience in the management of the patient with pancre-
atic cancer. It is becoming more and more difficult for gen-
eral surgeons to defend their preserves and to persist in
undertaking pancreatoduodenectomy once in a while. It is
high time for us to pay regard to the higher volume–better
outcome association for this particular operation.
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